After finishing the primary high-throughput screening, the screening team is often faced with thousands of hits to be evaluated further. Effective filtering of these hits is crucial in identifying leads. Mode of inhibition (MOI) study is extremely useful in validating whether the observed compound activity is specific to the biological target. In this article, the authors describe a highthroughput MOI determination method for evaluating thousands of compounds using an existing screening infrastructure. Based on enzyme or receptor kinetics theory, the authors developed the method by measuring the ratio of IC 50 or percent inhibition at 2 carefully chosen substrate or ligand concentrations to define an inhibitor as competitive, uncompetitive, or noncompetitive. This not only facilitates binning of HTS hits according to their MOI but also greatly expands HTS utility in support of the medicinal chemistry team's lead optimization practice. Three case studies are presented to demonstrate how the method was applied successfully in 3 discovery programs targeting either an enzyme or a G-protein-coupled receptor. (Journal of Biomolecular
INTRODUCTION
T HE ROLE OF HIGH-THROUGHPUT SCREENING (HTS) in drug discovery has been redefined and shifted in recent years. 1 In earlier years, advances in drug target identification and chemical compound library construction fueled the rapid growth of HTS technologies in the areas of robotic instrumentation, novel detection methodology, and efficient data analysis. More recently, attention has been focused on using established high-throughput infrastructure to alleviate other bottlenecks downstream in the drug discovery process. 2 Currently, most HTS labs have the capability to screen large compound libraries (100,000-1,000,000 compounds) for a variety of biological targets to find initial hits. However, further filtering of these initial hits is not always done systematically to provide researchers with quality leads to follow. Due to the complexity and low throughput of the mode of inhibition (MOI) determination, the MOI for hits is often not available to researchers. Knowledge of the MOI for enzymes and receptors is a powerful tool to bin the compounds 3 and to filter out nonspecific hits. [4] [5] [6] In certain cases, there is a need to pursue leads with one type of MOI instead of another. 7 The conventional method of MOI determination is low throughput. Consequently, MOI studies are usually limited to only a small number of compounds and performed at a later stage of the lead identification and optimization process. The MOI information thus is often not available for a large number of compounds and not available early enough in the drug discovery process to have optimal utility in selecting lead compounds.
In this article, we describe a method with theory and application for high-throughput determination of MOI for inhibitors of enzyme targets and for antagonists of G-protein-coupled receptor (GPCR) targets. The presented method is not intended to replace the traditional MOI analysis in its role of detailed characterization of a compound but rather to provide a highthroughput alternative in evaluating MOI for a large number of hits that emerge either from an HTS campaign or from medicinal chemistry lead optimization efforts. We present 3 case studies of the high-throughput MOI analysis application. In the first case, we routinely analyzed MOI during lead optimization for a project in which the MOI of a compound was an important optimization parameter. In the second case, we analyzed about 2000 kinase screening hits to categorize adenosine triphosphate (ATP) competitive and noncompetitive inhibitors. In the third case, we used the high-throughput method to determine MOI of antagonist hits of a GPCR target and compared the result to that of the Schild analysis.
MATERIALS AND METHODS

Protein tyrosine phosphatase 1B enzyme assay
The catalytic domain (residues 1-298) of human protein tyrosine phosphatase (PTP1B) with an N-terminal His tag was expressed in Escherichia coli and purified to homogeneity. The PTP1B activity in the presence of compounds or DMSO was assayed by measuring p-nitrophenol produced by dephosphorylation of p-nitrophenylphosphate (pNPP). 8, 9 For IC 50 measurement, the reaction contained 5 nM PTP1B, specified concentration of the compound, and 1 mM pNPP in Tris-bis-propane buffer (pH 7.0), with 0.1 mg/mL of bovine serum albumin (BSA), and was conducted at room temperature. The initial reaction rates were measured by monitoring the increase of absorbance at 410 nm due to the production of p-nitrophenol. The initial reaction rates were plotted and fit to the sigmoidal dose-response curve to obtain IC 50 values of the compounds (GraphPad Prism 3.0). For MOI analysis, the final pNPP concentrations in reactions varied between 1.0 and 20 mM. The initial reaction rates of these reactions were fit to the Michaelis-Menten equation by nonlinear regression analysis (GraphPad Prism 3.0).
Kinase enzyme assay
The catalytic domain of the target kinase with an N-terminal His tag was expressed using baculovirus-infected insect cells and purified using Talon chromatography. The catalytic activity was assayed by measuring the phosphorylation of a biotin-labeled peptide via a time-resolved fluorescence resonance energy transfer (TR-FRET) method. 10 Reactions contained 0.4 nM purified enzyme, 500 nM peptide substrate, and 30 µM ATP in assay buffer with 50 mM Tris (pH 7.8), 100 mM NaCl, 10 mM MgCl 2 , 5 mM DTT, and 0.1 mg/mL BSA. Reactions proceeded at room temperature for 1 h and then were stopped with a mixture of 15 mM EDTA, 100 nM Streptavidin-APC, and 2 nM Europium-Py20 antibody (PerkinElmer, Boston). TR-FRET signal was measured on a Fusion plate reader (PerkinElmer). Primary screening and reconfirmation tests were performed under the same conditions described above. The reconfirmation test was carried out in triplicate, and the result values were averaged.
GTPγ γ S binding assay for the target GPCR
Membranes were prepared from 293E cells transiently transfected with the target GPCR and Gαo protein. The binding buffer contained 20 mM HEPES (pH 7.4), with 10 mM MgCl 2 , 100 mM NaCl, and 0.01 mg/mL saponin. The final binding mixture contained 40 µg/mL membranes, 3 nM 35 S GTPγS (GE Healthcare Bio-Sciences Corp, Piscataway, NJ), 50 µM guanosine diphosphate (GDP), specified concentration of ligand and antagonist, and 2 mg/mL of wheatgerm agglutinin polyvinyltoluene (WGA PVT) beads (GE Healthcare Bio-Sciences Corp). The binding was carried out in 2 steps. Membranes, 35 S GTPγS and compounds were first incubated for 30 min. WGA PVT beads were then added, and plates were shaken for 30 min. Scintillation signals were measured on a TopCount reader (PerkinElmer). For Schild analysis, the ligand dose curves were determined at various concentrations of the antagonist. The dose ratio was calculated as the ratio of EC 50 of the ligand in the presence of antagonist over EC 50 of the ligand in the absence of antagonist. The logarithm of dose ratio minus 1 was plotted against the logarithm of the antagonist concentration and analyzed by linear regression (GraphPad Prism 3.0). A linear relationship with a slope of 1 indicated competitive MOI. The X-intercept was the logarithm of the antagonist binding constant K B .
THEORY FOR HIGH-THROUGHPUT MOI ANALYSIS
A typical HTS lab routinely measures IC 50 values for a large number of compounds with good accuracy. Automated compound serial dilution and batch data analysis make it practical to run hundreds of IC 50 measurements daily per person. The high precision of liquid-handling instruments allows reproducible IC 50 measurements. Our approach to a high-throughput MOI analysis uses IC 50 or percent inhibition measurements of inhibitors or antagonists. IC 50 and percent inhibition of an inhibitor or antagonist vary with the concentration of substrate or ligand according to its MOI. The IC 50 or percent inhibition shift at 2 selected substrate or ligand concentrations can be calculated based on classical enzyme or receptor kinetics. The MOI of an inhibitor or antagonist, therefore, may be predicted by these IC 50 or percent inhibition changes under different substrate or ligand concentrations. In the following text, we describe how IC 50 and percent inhibition vary with substrate or ligand concentration for inhibitors or antagonists with various MOI. Furthermore, we present the derivations of equations to calculate IC 50 ratios and percent inhibition relationships at 2 selected substrate or ligand concentrations for inhibitors or antagonists with a defined MOI. The following equations and derivations are based on a single substrate enzyme system. For multiple substrate systems, a detailed enzyme kinetics study should be performed to determine the sequence of substrate binding. Then one may be able to study the MOI of inhibitors with respect to the substrate of interest by fixing the concentrations of the remaining substrates.
Ratio of IC 50 values at 2 selected substrate concentrations for inhibitors with a defined MOI
The relationship of IC 50 , substrate concentration [S], K i of the inhibitor, and K m of the substrate has been described by Cheng and Prusoff 11 for inhibitors with various MOI.
For competitive inhibitors:
(1)
For mixed inhibitors:
For uncompetitive inhibitors:
These equations contain definitions and terminologies of enzyme kinetics. The readers are referred to related literature for more comprehensive descriptions. 12, 13 Briefly, K m is the Michaelis-Menten constant for the substrate. IC 50 is the concentration of the inhibitor required to achieve a half-maximal degree of inhibition. Competitive inhibitors bind exclusively to the free enzyme with a dissociation constant K i . Uncompetitive inhibitors bind exclusively to the enzyme-substrate complex with a dissociation constant αK i , where α is a multiplying factor. Mixed inhibitors bind to free enzyme with the dissociation constant K i and to the enzymesubstrate complex with the dissociation constant αK i . A common mixed MOI occurs when α equals unity and the inhibitor binds to the free enzyme and enzyme-substrate complex with equal potency. It is referred to as noncompetitive inhibition in this article. For noncompetitive inhibitors, IC 50 equals K i .
Based on equations (1) For competitive inhibitors:
For a defined enzyme-substrate system and selected substrate concentrations, IC S2 50 /IC S1 50 is a constant value for any competitive and uncompetitive inhibitors. For mixed inhibitors, IC S2 50 /IC S1 50 falls in between the values for competitive and uncompetitive inhibitors and is a function of the α value. Let us consider a hypothetical enzyme-substrate system where K m is 10 µM, [S 1 ] is 1 µM, and [S 2 ] is 100 µM. The following results are obtained from equations (4) through (6) .
For competitive inhibitors: IC S2
50 /IC S1 50 = 10. For mixed inhibitors: IC S2 50 /IC S1 50 = (10 * α + 1)/(α + 10).
For noncompetitive inhibitors (α equals 1): IC S2 50 /IC S1 50 = 1. For uncompetitive inhibitors: IC S2 50 /IC S1 50 = 0.1.
Compound MOI may be derived from the comparison of experimentally determined IC 50 ratios to the calculated values. Our first case study illustrates the application of this method.
Derivation of the equation for the percent inhibition relationships at 2 selected substrate concentrations
The percent inhibition, when measured at 2 selected substrate concentrations, can also be used to predict compound MOI. We begin the derivation with the dose-response curves of enzyme inhibition described by the following equation: 11
where ν i is the initial velocity in the presence of the inhibitor at concentration [I], and ν o is the initial velocity in the absence of the inhibitor. Percent inhibition of an inhibitor (%INH) at any given inhibitor concentration is
Substituting equation (7) into (8) 
We designate X as the percent inhibition at [S 1 ] and IC S1 50 as the IC 50 of an inhibitor when [S] equals [S 1 ]. We designate Y as the percent inhibition at [S 2 ] and IC S2 50 as the IC 50 of the inhibitor when [S] equals [S 2 ]. According to equation (9), X and Y can be expressed by equations (10) and (11), respectively:
Rearranging equations (10) and (11) gives
For inhibitors with a defined MOI, the R value can be calculated from equations (4) through (6) . Let us consider the same hypothetical enzyme-substrate system defined in the previous section. In a system where K m is 10 µM, [S 1 ] is 1 µM, and [S 2 ] is 100 µM, the following equations are obtained:
For competitive inhibitors: Y = X/(10 -0.09X).
For uncompetitive inhibitors: Y = X/(0.1 + 0.009X).
For noncompetitive inhibitors
The simulation plots of these equations are shown in Figure 1 . Competitive inhibitors fall onto the curve of the squares. Noncompetitive inhibitors fall onto the curve of the circles. Uncompetitive inhibitors fall onto the curve of the triangles. Mixed inhibitors with α < 1 are to be found in the area enclosed by the triangles and circles. Mixed inhibitors with α > 1 are to be found in the area enclosed by the circles and squares. In practice, experimentally obtained Y and X for compounds can be plotted and compared to the simulated curves for the prediction of compound MOI. Our second case study shows that this method is useful for analyzing thousands of screening hits.
Ratio of IC 50 values at 2 selected ligand concentrations for antagonist with defined MOI
The relationship of IC 50 of an antagonist with competitive and allosteric MOI, K B of the antagonist, ligand concentration [A], and EC 50 of the ligand has been described in the following equations: 14 For competitive antagonist:
For allosteric antagonist:
The definition of competitive and allosteric MOI can be found in the above reference, where α is the multiplying factor of the ligand affinity for the receptor imposed by the binding of the allosteric antagonist. Based on equations (13) and (14), the ratio (R) of 2 IC 50 values of an antagonist under 2 selected ligand concentrations ([A 1 ] and [A 2 ] , [A 1 ] < [A 2 ]) is calculated as follows:
For competitive antagonists:
For allosteric antagonists:
Antagonist MOI may be derived from the comparison of experimentally determined IC 50 ratios to the calculated values. Our third case study illustrates the application of this method.
APPLICATIONS OF HIGH-THROUGHPUT MOI ANALYSIS
Case 1: Determining MOI for PTP1B inhibitors during lead optimization
PTP1B is known to be prone to inhibition by promiscuous inhibitors. 4 Promiscuous inhibitors inhibit enzyme activities by a mechanism other than binding to a specific pocket on the enzyme. These molecules show little structure-activity relationship (SAR), have poor selectivity, and are not valid starting points for medicinal chemistry. The precise mechanism of the inhibitory activity imposed by promiscuous inhibitors is not fully understood. One prevailing hypothesis suggests that promiscuous inhibitors form aggregates that either sequester or denature the enzyme. 15 As a result, the inhibition is independent of substrate concentration, which leads to noncompetitive kinetic behavior. The noncompetitive MOI is one of the characteristics of the promiscuous inhibitors.
In our efforts to optimize a potent PTP1B inhibitor series, we found that although the lead compounds were competitive inhibitors of PTP1B, some analogues of the series displayed noncompetitive or mixed kinetic behavior that was a result of the promiscuous inhibition. Therefore, optimization of the PTP1B inhibitors required maintaining the competitiveness of the compounds in addition to enhancing the potency and improving pharmacokinetics properties. It became essential to develop a high-throughput method to evaluate MOI of up to 100 compounds per week.
We measured IC 50 values of the compounds at 2 selected substrate concentrations and compared the IC 50 ratios to the calculated value for competitive or noncompetitive inhibitors. K m of substrate pNPP was measured to be 1.4 mM. Because the primary goal was to distinguish competitive and noncompetitive inhibitors, we selected the 2 substrate concentrations so that the separation of R values for competitive and noncompetitive inhibitors is significant. [S 1 ] was selected as 1.0 mM, and [S 2 ] was 20 mM. The ratio of IC 50 at 20 mM pNPP over IC 50 at 1 mM pNPP was calculated to be 8.9 for competitive inhibitors and 1.0 for noncompetitive inhibitors, according to equations (4) and (5).
To validate the method, we first analyzed a set of competitive and noncompetitive inhibitors whose MOI was determined by the conventional kinetic analysis based on steady-state analysis of reaction rates at various substrate and inhibitor concentrations. 8, 9 The statistical analysis of 31 measurements of competitive inhibitors and 18 measurements of noncompetitive inhibitors is summarized in Table 1 . The IC 50 ratio R value for competitive compounds was 9.0, with a standard deviation of 1.2. The R value for noncompetitive compounds was 1.0, with a standard deviation of 0.3. Hence, a single measurement of the R value can distinguish competitive inhibitors from noncompetitive inhibitors with great confidence. For mixed compounds, the R values fall in between 1.0 and 9.0. The exact value of R is dependent on the proportion of the competitive component relative to the nonspecific component of the compound. Table 2 shows the measurements of R values for a number of compounds with mixed MOI. The results suggest that this method is able to distinguish certain mixed inhibitors from competitive and noncompetitive inhibitors. Using these R values and standard deviation of their measurement as a guide, we applied this method to analyze the MOI for lead optimization compounds. We were able to distinguish compounds with competitive, noncompetitive, or mixed MOI. The results were consistent with conventional MOI analysis (data not shown).
Case 2: Identifying MOI with respect to ATP for hits from HTS of a kinase target
The goal of this project was to screen our compound collection for inhibitors of a target kinase and to bin the screen hits into ATP competitive and ATP noncompetitive inhibitors. This enabled the hit series selection decision to be based not only on potency and structural tractability of the hits but also on MOI. ATP competitive hits interact with the ATP binding site on the kinase, whereas ATP noncompetitive hits interact with other sites on the kinase. Drawbacks for ATP competitive inhibitors, including significantly reduced potency due to the high cellular ATP concentration and lesser degree of selectivity against other kinases, have been widely documented in the literature. 16 On the other hand, some ATP noncompetitive kinases inhibitors have been shown to be promiscuous inhibitors. 6 As a result, noncompetitive hits need to be evaluated mechanistically to rule out the possibility of promiscuous inhibition before chemistry follow-up.
The kinase reaction is a 2-substrate system. For our target kinase, enzyme kinetics studies showed it to be randomly ordered in terms of 2 substrates binding (data not shown). Therefore, we can apply equations derived from a single substrate system to study MOI of inhibitors with respect to ATP when the peptide substrate concentration is fixed. 3 We screened ~330,000 compounds for inhibitors of the target kinase. About 270,000 compounds were from a general compound collection, and ~60,000 compounds were from a designed kinase inhibitor library. The primary screen yielded 2300 hits with greater than 57% inhibition at 10 µM, which were cherry-picked for reconfirmation and further studies. Given the large number of primary hits, it was not practical to measure IC 50 shift at 2 selected substrate concentrations. We approached MOI for these hits by determining percent inhibition of each compound under 2 ATP concentrations. The lower ATP concentration was 30 µM, which is the K m of ATP for the target kinase. The higher ATP concentration was 300 µM. The functional relationship of the 2 percent inhibitions for competitive inhibitors was calculated using equations (4) and (12): Y = X/(5.5 -4.5 * X/100). (17) The functional relationship of the 2 percent inhibitions for noncompetitive inhibitors was calculated using equations (5) and (12):
(18) Figure 2A shows a plot of percent inhibition for all screen hits at 10 µM compound and 300 µM ATP versus percent inhibition for the same compounds at 30 µM ATP. The hits clearly fell (18). Therefore, they are ATP noncompetitive inhibitors. Inhibition by the other group of compounds decreases with the increase of ATP concentration. They cluster around the curved line that is simulated based on equation (17) . The MOI of these compounds is therefore projected to be ATP competitive. Because the 2 lines intersect at 100% inhibition, it is less reliable to predict MOI for compounds that inhibit more than 80% at 10 µM. We thus determined the percent inhibitions at 2 µM compounds under the above 2 ATP concentrations. The analysis, shown in Figure 2B , allowed us to determine MOI of the potent inhibitors.
In summary,~2000 compounds were reconfirmed as hits with greater than 50% inhibition at 10 µM, of which 1655 were projected to be ATP competitive and 337 were ATP noncompetitive. Interestingly, all 167 confirmed hits that were from the focused kinase inhibitor library were competitive inhibitors except for 3 compounds. These 3 compounds also inhibited other enzymes (data not shown) with similar potency (IC 50 values are ~10 µM). They were likely promiscuous inhibitors. 15 This observation was consistent with the fact that the kinase-focused library was designed based on known ATP competitive scaffolds and validated using the percent inhibition shift method for identification of competitive and noncompetitive hits.
Case 3: Determining MOI for antagonist hits from HTS of a GPCR target
We screened 30,000 compounds from a subset of our internal compound library against a GPCR target for antagonists and identified 30 hits belonging to a few chemical series. Because 125 I-labeled ligand for this GPCR lost its function, we could not develop a direct ligand displacement assay to study the MOI of these GTPγS assay hits. We therefore applied the IC 50 shift method using the GTPγS assay. The EC 50 of the unlabeled ligand for the target GPCR was measured to be 60 nM. We selected 60 nM and 600 nM as [A 1 ] and [A 2 ]. The IC 50 ratio under these conditions was calculated to be 5.5 for competitive antagonists using equation (15) . Because the assay signal to background window is relatively low (S/B = 3, Z´ factor 17 = 0.65), IC 50 was measured in triplicate, and the average of the triplicates was used for the calculation of IC 50 ratios. The Schild analysis was performed for representative compounds from each series. Figure 3 shows such an analysis for a typical competitive antagonist. Table 3 shows the results of IC 50 ratio analysis of all analogues from this competitive antagonist series. All the analogues of this competitive antagonist appeared to be competitive based on IC 50 ratio analysis. Compounds from other series were confirmed not to be competitive antagonists by both IC 50 ratio analysis and Schild analysis (data not shown).
DISCUSSION
Determining the MOI for a large number of compounds has not been a common practice for drug discovery programs in the pharmaceutical or biotech industry. There is, however, increasing interest in understanding MOI of screening hits or lead compounds from rational designs at the early stage of a drug discovery program to facilitate the selection and prioritization of series with the best follow-up potential. 3 This article described the theoretical basis and practical applications of IC 50 and percent inhibition measurements at various substrate or ligand concentrations for predicting MOI for enzyme inhibitors or antagonists of GPCRs. The method can be best used in an organization where a large number of screening hits or synthesized chemical compounds need to be characterized for their MOI.
In the first case study, we applied the IC 50 shift method to determine MOI for PTP1B enzyme inhibitors. More than 900 compounds for this project were analyzed with the IC 50 shift method to bin them into 1 of the 3 categories: competitive, noncompetitive, and mixed inhibition. This large-scale MOI study was not practical with the conventional method. Moreover, we could not use cell-based assays to rule out promiscuous inhibitors, especially those with mixed inhibition because legitimate enzymatic activity does not always translate into cell-based activity due to poor cellular uptake of many PTP1B inhibitors. Thus, the IC 50 shift method for MOI determination proved to be an indispensable tool to rule out promiscuous inhibitors for our PTP1B project.
In the second case study, we expanded the application to thousands of screening hits by using the percent inhibition shift method. Measuring the IC 50 values of screening hits requires a significant amount of compound handling work because most companies prepare the compounds from solid samples rather than using liquid stock for IC 50 measurement. At this stage, the usefulness of screening hits is not great enough to justify such a large-scale IC 50 measurement. The percent inhibition shift method effectively binned more than 2000 kinase screening hits into ATP competitive and noncompetitive categories. Researchers used the data to make more informed decisions regarding which hits should be followed up.
In the third case study, we explored the feasibility of applying the IC 50 shift method to receptors rather than enzymes. Due to the lack of a direct ligand displacement assay to determine whether the hits were competitive, allosteric, or simply promiscuous inhibitors, we carried out MOI analysis by using the IC 50 shift method in the GTPγS assay and identified 1 series of hits as competitive antagonists. This series was further confirmed as competitive antagonists by Schild analysis.
A couple of considerations should be explored when designing experiments for high-throughput MOI analysis based on IC 50 shift under 2 substrate or ligand concentrations. The quality of the assay needs to be robust enough to generate reliable IC 50 ratio measurements under the varied substrate or ligand concentrations. It is often possible to improve the accuracy by increasing the number of IC 50 measurements. For assays with Z´ factors less than 0.8, we usually apply the method with duplicate or triplicate IC 50 measurement. We also ensure that substrate consumption is kept below 30% to minimize its effect on IC 50 values. Second, the IC 50 ratio differences for competitive, noncompetitive, and Schild analysis was carried out for compound 1 and showed competitive mode of inhibition (Fig. 3) . The calculated ratio is 5.5 for competitive antagonists. Each IC 50 was the average of 3 measurements.
uncompetitive inhibitors are, to a great extent, dependent on the choice of substrate or ligand concentrations. R value is 1 for noncompetitive inhibitors or antagonists, R is greater than 1 for competitive inhibitors or antagonists, and R is less than 1 for uncompetitive inhibitors or antagonists. To distinguish among all types of inhibitors or antagonists, the substrate or ligand concentrations should be selected so that the separation of R values for the inhibitors with various MOI is large enough to be determined reliably. Figure 4 demonstrates the change of R value with respect to [S 1 ] and [S 2 ] for certain MOI. is selected at least 10-fold of [S 1 ], assuming the assay is more robust at higher substrate concentrations.
To design experiments for high-throughput MOI analysis based on percent inhibition shift under 2 substrate or ligand concentrations, the requirement for assay quality is more stringent than that of the IC 50 shift method. We usually only apply the method to assays with a Z´ factor higher than 0.8. In addition, inhibitor concentration should be carefully chosen to achieve maximal separation of percent inhibitions for competitive inhibitors at 2 substrate or ligand concentrations. As demonstrated in Figure 2 , we used 2 inhibitor concentrations to characterize both potent and weak inhibitors.
It is often effective to use high-throughput MOI analysis in conjunction with the classical MOI analysis. For example, if the MOI of a series of inhibitors has been established by the classical MOI analysis, the HTS MOI method can be used to monitor the change of MOI in compounds as the lead optimization progresses. Alternatively, the HTS MOI method can be used to evaluate all hits from an HTS campaign. A small number of representatives can then be followed up with conventional MOI analysis to confirm HTS MOI results and to get more detailed information.
In summary, we have demonstrated a high-throughput MOI determination method based on the IC 50 or percent inhibition measurement. The method was applied successfully to both enzyme and receptor targets. It was also implemented productively in lead identification and lead optimization in our drug discovery programs.
